Solvotrin Therapeutics
Financials
Estimates*
EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|
EBITDA | <1m | <1m | <1m | 1.1m | <1m | <1m |
Profit | <1m | <1m | <1m | <1m | <1m | <1m |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | €2.6m | Early VC | |
N/A | €1.1m | Early VC | |
N/A | €2.0m | Early VC | |
€6.7m Valuation: €45.0m 41.4x EV/LTM EBITDA | Late VC | ||
Total Funding | $13.6m |
Recent News about Solvotrin Therapeutics
EditSolvotrin Therapeutics is a privately held Irish healthcare and medicine development company focused on optimizing established therapies, vitamins, and minerals using innovative science to address significant unmet clinical needs. The company operates in the life sciences and pharmaceutical market, targeting both healthcare providers and patients who require improved therapeutic options. Solvotrin's business model revolves around research and development, creating proprietary formulations that enhance the effectiveness and tolerance of existing treatments, such as iron and aspirin. Revenue is generated through product sales, partnerships, and licensing agreements with major pharmaceutical companies. The company has successfully launched products like Active Iron and is expanding its market reach into Europe and China through strategic partnerships. Solvotrin's commitment to innovation and clinical excellence positions it as a key player in the healthcare industry.
Keywords: healthcare, medicine development, innovative science, clinical needs, iron supplements, aspirin optimization, life sciences, pharmaceutical partnerships, product sales, research and development.